1	A highly sensitive and specific SARS-CoV-2 spike- and nucleoprotein-based			
2	fluorescent multiplex immunoassay (FMIA) to measure IgG, IgA and IgM			
3	class antibodies			
4				
5	Authors			
6	Anna Solastie <sup>1</sup> , Camilla Virta <sup>1</sup> , Anu Haveri <sup>1</sup> , Nina Ekström <sup>1</sup> , Anu Kantele <sup>2</sup> , Simo Miettinen <sup>3</sup> , Johanna			
7	Lempainen <sup>4</sup> , Pinja Jalkanen <sup>5</sup> , Laura Kakkola <sup>5</sup> , Timothée Dub <sup>6</sup> , Ilkka Julkunen <sup>5,7</sup> , Merit Melin <sup>1</sup>			
8				
9	Corresponding author: Anna Solastie, anna.solastie@thl.fi			
10				
11	<sup>1</sup> Department of Health Security, Expert Microbiology Unit, Finnish Institute for Health and Welfare,			
12	Helsinki, Finland			
13	<sup>2</sup> Meilahti Infectious Diseases and Vaccination Research Center, MeiVac, Department of Infectious			
14	Diseases, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.			
15	<sup>3</sup> Department of Virology, University of Helsinki			
16	<sup>4</sup> Department of Pediatrics, University of Turku and Turku University Hospital and Immunogenetics			
17	Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland			
18	<sup>5</sup> Infection and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland			
19	<sup>6</sup> Department of Health Security, Infectious Disease Control and Vaccinations Unit, Finnish Institute			
20	for Health and Welfare, Helsinki, Finland			
21	<sup>7</sup> Clinical Microbiology, Turku University Hospital, Turku, Finland			

### 22 Abstract

23 Background. Validation and standardization of accurate serological assays are crucial for the 24 surveillance of the coronavirus disease 2019 (COVID-19) pandemic and population immunity. Methods. We describe the analytical and clinical performance of an in-house fluorescent multiplex immunoassay 25 26 (FMIA) for simultaneous quantification of antibodies against the severe acute respiratory syndrome 27 coronavirus 2 (SARS-CoV-2) nucleoprotein and spike glycoprotein. Furthermore, we calibrated IgG-FMIA against World Health Organisation (WHO) International Standard and compared FMIA results to 28 29 an in-house enzyme immunoassay (EIA) and a microneutralisation test (MNT). We also compared the 30 MNT results of two laboratories. Results. IgG-FMIA displayed 100% specificity and sensitivity for samples collected 13-150 days post-onset of symptoms (DPO). For IgA- and IgM-FMIA 100% 31 32 specificity and sensitivity were obtained for a shorter time window (13-36 and 13-28 DPO for IgA- and 33 IgM-FMIA, respectively). FMIA and EIA results displayed moderate to strong correlation, but FMIA was overall more specific and sensitive. IgG-FMIA identified 100% of samples with neutralising 34 antibodies (NAbs). Anti-spike IgG concentrations correlated strongly ( $\rho=0.77-0.84$ ,  $P<2.2x10^{-16}$ ) with 35 NAb titers. The NAb titers of the two laboratories displayed a very strong correlation ( $\rho=0.95$ , 36  $P < 2.2 \times 10^{-16}$ ). Discussion. Our results indicate good correlation and concordance of antibody 37 38 concentrations measured with different types of in-house SARS-CoV-2 antibody assays. Calibration 39 against WHO international standard did not, however, improve the comparability of FMIA and EIA results. 40

41

keywords: SARS-CoV-2, COVID-19, antibody, immunoassay, nucleoprotein, spike glycoprotein, WHO
international standard, neutralising antibodies, microneutralisation, receptor-binding domain

44

### 45 Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), had claimed over 4 million lives and infected 190 million by late July 2021 [1]. A large proportion of all infections may go undetected in their acute phase [2,3] for various reasons, such as lack of symptoms [4,5] or hesitancy of getting tested [6]. Therefore, accurate serological assays are needed to provide more reliable estimates of COVID-19 prevalence.

51 SARS-CoV-2 serological assays are useful anywhere between determining seroprevalence 52 in the general population to the investigation of confined outbreaks. In neutralisation tests and other 53 serological tests alike, the clinical specificity and sensitivity of the assays can vary considerably [7–12]. 54 Comparisons of methods and their standardisation is urgently needed to properly understand and apply 55 the vast acquired information on the immunity induced by SARS-CoV-2 infection and COVID-19 56 vaccines.

We describe the validation and performance of an in-house fluorescent multiplex 57 58 immunoassay (FMIA) developed for quantification of antibodies produced against three SARS-CoV-2 antigens: the full-length spike glycoprotein (SFL), spike receptor-binding domain (RBD) and 59 60 nucleoprotein (N). Our assay detects antibodies against these three antigens simultaneously, which 61 enables differentiation of natural SARS-CoV-2 infection from vaccine-induced immunity. The assay is 62 based on an FMIA previously described by Trivedi et al. [13]. We have recently reported the performance 63 of the FMIA for measuring IgG antibodies against SARS-CoV-2 nucleoprotein [14]. Here, we report our findings on the analytical and clinical performance of FMIA and compare its IgG, IgA and IgM assay 64 65 results to another laboratory's in-house enzyme immunoassay (EIA) [15,16], both calibrated for IgG with 66 WHO International Standard [17]. Furthermore, we compare FMIA antibody levels to neutralising

antibody (NAb) titers [14,18] and NAb titers of microneutralisation tests (MNTs) between two separate
laboratories.

69

### 70 Materials and methods

#### 71 Serum samples

72 We assessed the analytical and clinical performance of the FMIA by using negative and positive sample panels. The negative sample panel consisted of 402 anonymous serum samples collected in mid-2019 73 before the COVID-19 pandemic. The positive serum panel consisted of 147 samples collected from 58 74 75 volunteers 4-150 days post-onset of symptoms (DPO) and 0-147 days post positive PCR test result for 76 SARS-CoV-2. Samples were collected as part of a COVID-19 household transmission study [19]. We 77 used the negative and positive serum panels also to compare FMIA and MNT results. We excluded one 78 sample due to limited sample volume leaving the total sample size to n=548. Details of the panels are 79 presented in Table S1 and Figure S1.

80 We compared FMIA with EIA using a serum panel that consisted of a subset of 80 samples collected as part of a COVID-19 mRNA vaccine response study [16]. We collected the samples from 81 82 convalescent-phase PCR-confirmed COVID-19 patients (n=20) and volunteer health care workers 83 (n=20) who received two doses of Pfizer-BioNTech BNT162b2 mRNA vaccine. We recruited the 84 convalescent COVID-19 patients among outpatients with a positive RT-PCR positive test result in the 85 Helsinki University Hospital database and collected serum samples 15-41 (median 26) DPO. We collected sera from 20 vaccinated volunteers before or on the day of the vaccination (day 0 samples), 86 three weeks (median 21 days, range 18-21) post 1<sup>st</sup> vaccine dose (3-week samples), and six weeks 87 88 (median 48 days, range 39-50) post 1<sup>st</sup> vaccine dose (6-week samples). At the time of the 6-week sample collection, three weeks (median 27 days, range 18-29) had also passed from the 2<sup>nd</sup> vaccine dose.
Participant demographics are presented in Table S1.

91

#### 92 The SARS-CoV-2 FMIA

Here, we adapted the previously described SARS-CoV-2 FMIA [14] for the measurement of IgG, IgA 93 94 and IgM antibodies against SARS-CoV-2 RBD, SFL and N antigens. Briefly, we conjugated SARS-95 CoV-2 RBD (product code: REC31849), SFL (REC31868) and N (REC31812, the Native Antigen 96 Company) antigens on the surfaces of MagPlex®-C superparamagnetic carboxylated microspheres 97 (Luminex) by carbodiimide reaction. We added the microspheres onto black 96-well plates (Costar 3915) 98 with diluted sera, reference and control samples and incubated RT with shaking at 600 rpm in the dark 99 for 1 hour. We washed the unbound particles away with a magnetic plate washer (ELx405 and 405TSRS, 100 BioTek), and added R-Phycoerythrin-conjugated Affinipure Goat Anti-Human IgG, IgA or IgM Fcy 101 Fragment Specific detection antibodies (Jackson Immuno Research) to the wells. We incubated the plates 102 for 30 minutes as described above and then washed them again. We measured the median fluorescence 103 intensity (MFI) with MAGPIX® system (Luminex). MFI values were automatically converted into 104 antibody concentration (FMIA U/ml) via interpolation from 5-parameter logistic (5-PL) curves 105 (xPONENT software version 4.2, Luminex) created from serially diluted (1:400–1:1638400) in-house 106 reference serum. We gave the 1:400 dilution of the standard an arbitrary concentration of 100 FMIA 107 U/ml. We performed the FMIA analyses at the Finnish Institute for Health and Welfare (Helsinki, 108 Finland). A full description of the FMIA method is presented in Supplementary Material.

109

#### 110 Evaluation of the analytical performance of FMIA

# 111 **Limit of detection (LOD) and limit of quantification (LOQ).** We determined LOD and LOQ from 26

112 experiments by calculating the mean + 3x (LOD) and 8x (LOQ) standard deviation of MFI values

generated from blank wells (n=52). MFI values were converted into FMIA U/ml by interpolation from
the 5-PL reference curve with GraphPad Prism v9.

Linearity. We assessed the linearity of FMIA by comparing antibody concentration of serially diluted 115 116 (1:100, 1:200, 1:400, 1:800 and 1:1600) sera (IgG: n=6, IgA and IgM: n=7) collected as part of the 117 COVID-19 household transmission study [19]. Linearity was measured as Pearson correlation between dilution factor and antibody concentration, and mean  $R^2 \ge 0.95$  of all samples was considered acceptable. 118 119 Precision and reproducibility. We assessed the precision and reproducibility of FMIA as the mean 120 percentage of the coefficient of variation (CV%) of antibody concentrations between samples analysed 121 repeatedly in different settings. Precision was assessed as intra- and inter-assay variation and 122 reproducibility by comparing the results obtained by three laboratory technicians and as variation caused 123 by different batches of crucial reagents. A full description of the evaluation of analytical performance is 124 presented in Supplementary Material.

125

#### 126 Evaluation of the clinical performance of FMIA

We determined the clinical performance of the antibody assays as their ability to distinguish negative-(pre-COVID19 era) and positive panels' (PCR confirmed patients') sera. We determined the thresholds for positivity by comparing all possible threshold combinations for the three antigens with R (version 3.6.0) and RStudio (version 1.2.1335). We prioritised a specificity of 100% and determined it with the entire negative serum panel (n=402). Sensitivity was assessed separately for subgroups of the positive serum panel's samples (n=147) based on DPOs.

133

134 **EIA** 

135 The SARS-CoV-2 EIA used in this study has previously been described in detail [15]. We measured IgG,

136 IgA, IgM and total Ig antibodies against SARS-CoV-2 S1 and N proteins from sera diluted 1:300. SARS-

137 CoV-2 S1 (GenBank ID: MN908947.3) and N (Genbank ID: NC\_045512.2) antigens were expressed 138 and purified, and antigen-specific antibody levels were measured with a Victor Nivo device 139 (PerkinElmer) as described previously [16]. We converted the results into EIA units by comparing the 140 absorbance values of samples with the absorbance values of 1:300 diluted positive control (marked as 141 100 EIA units) and 1:300 diluted negative control (marked as 0 EIA units) included in each assay. 142 Thresholds for positivity were previously determined with 20 negative sera [16]. We performed the EIA 143 analyses at the University of Turku (Turku, Finland).

144

#### 145 Calibration against WHO International Standard

146 We calibrated the FMIA's IgG specific in-house reference serum against a WHO International Standard 147 (NIBSC code 20/136 [17]). We serially diluted the in-house reference serum and WHO international 148 standard and assigned the 1:100 dilution of the WHO international standard a concentration of 10 binding 149 antibody units (BAU)/ml. We conducted the analysis on two separate days and interpolated the mean 150 concentration for each dilution of the in-house reference serum from the linear range of the WHO 151 international standard. With EIA, we used the WHO international standard to calibrate the positive 152 control by diluting both 1:300 and calculating their ratio. We performed the EIA analysis once and used 153 the average absorbance values calculated from duplicate wells. We obtained a calibration factor for each 154 antigen separately and used them to convert FMIA U/ml and EIA units into BAU/ml.

155

#### 156 Microneutralisation tests

MNT of laboratory #1. The MNT of laboratory #1 was performed at the Finnish Institute for Health and Welfare (Helsinki, Finland) and the assay has been previously described in detail [14,18]. Briefly, the MNT of laboratory #1 was performed using Vero E6 cells and true duplicates of sera diluted serially from 1:4. After four days the cells were fixed with 30% formaldehyde and the cytopathic effect (CPE)

was measured. The viral strains used were hCoV-19/Finland/1/2020 (FIN-1) (GISAID accession ID EPI\_ISL\_407079) and hCoV-19/Finland/FIN-25/2020 (FIN-25) in the analysis of positive and negative serum panels, and FIN-1 in analyses of sera used in comparison to MNT of laboratory #2. A sample was considered positive when the NAb titer was  $\geq 6$  for at least one virus and negative when titers for both viruses were <4. Samples with titers between 6 and 4 for both viruses were considered borderline. Negative samples were given a titer value of 2 for statistical analyses. In cases where the titers of the two viruses differed, the titer of the sample was defined as the highest of the two.

168 **MNT of laboratory #2.** The MNT of laboratory #2 was performed at the University of Turku (Turku, 169 Finland) and the method has been previously described [16]. The MNTs between laboratories 1 and 2 170 differed in used viral isolate, serum dilution, cell line, incubation time and cell fixation. MNT of 171 laboratory #2 used VeroE6-TMPRSS2-H10 cells fixed with 4% formaldehyde and measured CPE after 172 three days. Starting dilution for sera was 1:20 with 50 TCID<sub>50</sub> of SARS-CoV-2 variant FIN-25 (EPI\_ISL\_412971, GenBank accession MW717675) and neutralisation titers were analysed in 173 174 duplicates. The NAb titer was defined as the last dilution resulting in 50% inhibition of cell death. The 175 threshold for positivity was >20. Negative samples were given a titer value of 10 for statistical analyses. 176 FIN-1 represents lineage B (D614G substitution) and FIN-25 represent lineage B.1 with three amino acid 177 substitutions (D614G, 41% R682W, 45% YQTQT 674-678 [16]) in the spike glycoprotein compared to 178 the Wuhan-Hu-1 strain.

179

### 180 Comparison of FMIA, EIA and MNT assays.

We calculated Spearman correlation coefficient ( $\rho$ ) and the statistical significance of the correlation between FMIA and EIA antibody concentrations and the two laboratories' NAb titers. In addition, we compared FMIA and EIA in their ability to detect antibodies induced by natural infection and vaccination. Samples that were borderline in MNT of laboratory #1 were considered as positives.

#### 185 Ethical statement

186 The investigations were carried out under the General Data Protection Regulation (Regulation (EU) 2016/679, directive 95/46/EC) and the Finnish Personal Data Act (Finlex 523/1999). The study protocols 187 188 for the collection of pre-COVID-19 pandemic samples and COVID-19 patient samples were approved 189 by the Helsinki-Uusimaa health district ethical permissions 433/13/03/00/15 and HUS/1238/2020. The 190 Finnish law on communicable diseases and the duties of the Finnish Institute for Health and Welfare 191 [20,21] allowed the implementation of the initial household transmission study without seeking further 192 institutional ethical review. A waiver of ethical approval was received from Prof. Mika Salminen 193 (Director of the Department for Health Security of the Finnish Institute for Health and Welfare). The 194 vaccinee cohort (n=20) was randomly selected from a larger cohort (n=180) of vaccinated healthcare 195 personnel of Turku University Hospital [16] approved by the Southwest Finland health district ethical 196 permission ETMK 19/1801/2020. Written informed consent was obtained from all volunteers.

197

### 198 **Results**

#### 199 Analytical performance of the FMIA

200 We calculated the LOQ and LOD separately for each antigen and each antibody class and the data is 201 presented in Table S2. For IgA and IgM assays, the linearity with different serum dilutions was excellent for all antigens (range  $R^2=0.96-1$ ). For the IgG assay, less diluted samples (dilutions 1:100 and 1:200) 202 203 resulted in relatively lower IgG concentrations leading to weaker linearity correlations. Exclusion of 204 dilutions 1:100 and 1:200 resulted in  $R^2 \ge 0.99$  for all antigens in the IgG assay. As a compromise to avoid 205 decreased clinical sensitivity and to minimize the number of serum dilutions, we decided to calculate 206 antibody concentrations from the average of 1:100 and 1:1600 dilutions for all except negative sample 207 panels sera, which analysed diluted 1:100.

The mean intra-assay variation ranged from 8 to 10% and inter-assay variation from 4 to 12% in the different antibody classes (Table S3). The mean variation between different technicians was 20% for IgG, 21% for IgA and 18% for IgM assays. The variation between four different batches of 20% conjugated microspheres was 16% and the variation between different batches of detection antibodies 212 was 15% for IgA and IgG assays. Overall, both intra- and inter-assay variation were found acceptable 213 for all antibody classes and antigens.

214

#### 215 Calibration against WHO international standard

216 The IgG specific concentrations against N, RBD and SFL of the in-house reference serum calibrated 217 against the WHO International standard [17] were 34, 18 and 23 BAU/ml, respectively. Because the starting dilution of IgG specific in-house reference sera was given an arbitrary concentration of 100 218 219 FMIA U/ml we multiplied the results by a factor of 0.34 for nucleoprotein, 0.18 for RBD and 0.23 for 220 SFL to obtain calibrated BAU/ml. In EIA, the calibration factor for N IgG was 12.9, for N total Ig 17.4, 221 for S1 IgG 11.8 and for S1 total Ig assay 12.0. We did not calibrate MNTs but obtained a titer of 192 222 against FIN-1 virus in laboratory #1 and 640 against FIN-25 in laboratory #2 for the WHO international 223 standard.

224

### 225 Clinical performance of the FMIA

We set the thresholds for positivity based on a positive panel of convalescent sera (n=147) and a negative serum panel (n=402) aiming to achieve 100% specificity. We considered a sample positive for anti-spike IgG antibodies (S-IgG) if it had  $\geq$ 0.13 and  $\geq$ 0.089 BAU/ml anti-RBD and anti-SFL IgG antibodies, respectively. With these thresholds, the specificity of the S-IgG FMIA was 100% [95% CI: 99.1–100] (Table 1). The sensitivity of the FMIA for detecting antibodies in convalescent sera was dependent on DPO (Table 1). The sensitivity of the S-IgG FMIA assessed based on the positive serum panel (DPO 4–

150, n=147) was 97% [95% CI: 93.2–98.9]. All samples with IgG concentrations under the thresholds
(n=7/147) were collected 4–11 DPO (Figure 1). The sensitivity of the S-IgG FMIA was 100% [95% CI:
97.3–100] for samples collected 13–150 DPO (n=140) (Table 1). With the positive serum panel used in
this study (n=147) the specificity and sensitivity of the N-IgG FMIA we have previously described [14]
was 100% for samples collected 21-51 DPO but the sensitivity of the assay decreased to 98% for samples
collected 52-150 DPO (Figure 2).

The optimal threshold for IgA-FMIA was also based on the simultaneous detection of both spike antibodies. We considered a sample positive for IgA antibodies if it contained  $\geq 11.4$  and  $\geq 3.88$ FMIA U/ml anti-RBD and anti-SFL IgA antibodies, respectively, which resulted in 100% specificity [95% CI: 99.1–100] (Table 1.). For samples collected 13–36 DPO (n=69), the sensitivity was 100% [95% CI: 94.7–100]. As DPO increased, sensitivity decreased as a lower number of the positive serum panel's samples reached the thresholds (Figure 2).

The optimal threshold for IgM-FMIA was based only on the concentration of anti-SFL antibodies, as the addition of RBD or N to the threshold criteria did not result in higher specificity or sensitivity. We considered samples that contained  $\geq 17.5$  FMIA U/ml anti-SFL IgM antibodies positive for IgM. The specificity of the IgM assay was 100% [95% CI: 99.1–100] with this threshold (Table 1). DPO range resulting in 100% sensitivity was 13–28 days for IgM [95% CI for sensitivity: 91.0–100, n=39] (Table 1). As DPO increased, the sensitivity of the IgM assay decreased steeply (Figure 2).

250

#### 251 Comparison of FMIA and MNT

NAb titers exhibited strong ( $\rho$ =0.77-0.84) and statistically significant correlation (P<2.2x10<sup>-16</sup>) with S-IgG concentrations (Figure 3). All samples that contained NAb were also positive in IgG-FMIA regardless of DPO (Table S4). Thereby the S-IgG FMIA was 100% [95% CI: 97.3-100] sensitive and 96% [95% CI: 91.1-98.4] specific for identification of NAb from samples taken 4-150 DPO. Some

samples were negative in MNT but positive for S-IgG in FMIA (Table S4) indicating that not all antibodies that bind to SFL and RBD antigens used in FMIA are neutralising. The ability of IgA- and IgM-FMIA to identify samples positive for NAbs was dependent on DPO in a manner similar to their clinical sensitivity, indicating the different kinetics of IgA and IgM compared to NAb antibodies (Table S4, Figure 2).

261

### 262 Comparison of FMIA and EIA

263 We compared the results of FMIA and EIA by analysing a panel of convalescent serum samples (n=20)264 and pre-and post-vaccination samples (n=60) of 20 subjects. We observed the strongest correlations 265 (p=0.94-0.95) between FMIA and EIA for IgG (FMIA) and IgG or total Ig (EIA) antibody concentrations against SARS-CoV-2 spike antigens (Figure 4). FMIA and EIA anti-spike antibody concentrations also 266 267 displayed a strong correlation in IgA and IgM assays ( $\rho=0.79$  for IgA,  $\rho=0.88$  for IgM, Figure S2). The correlation between anti-N concentrations of IgG FMIA and EIA was moderate ( $\rho=0.54$ , Figure 4). Thus, 268 269 FMIA and EIA differed to some extent in their ability to measure antibodies induced by SARS-CoV-2 infection and COVID-19 mRNA vaccination. 270

271 Of convalescent patient sera (14-60 DPO), 20/20 had anti-N and S-IgG antibodies in FMIA, 272 while 15/20 had anti-N and 11/20 anti-S1 in IgG EIA and 19/20 had anti-N and 17/20 had anti-S1 273 antibodies in EIA total Ig assay. Anti-spike IgA antibodies were identified in 18/20 of patients when 274 measured with FMIA but only 1/20 had anti-S1 IgA antibodies with EIA. Anti-spike IgM antibodies 275 were identified in 18/20 and 20/20 of patients with FMIA and EIA, respectively. Of the samples collected 276 before vaccination, 1/20 (IgG FMIA), 0/20 (IgG EIA) and 5/20 (EIA total Ig) had anti-N antibodies while 277 lacking anti-spike antibodies. Of samples collected at 3 weeks after vaccination, 20/20 were positive for 278 anti-spike IgG in FMIA and 18/20 in EIA; 20/20 samples were positive at 6 weeks with both assays.

When we compared the IgG concentrations in convalescent and post-vaccination samples measured with FMIA and EIA, the mean CV between FMIA U/ml and EIA units was 80%. The mean CV increased to 130% when results were converted to BAU/ml. Hence, calibration with the WHO standard did not increase the comparability of FMIA and EIA but increased the variation between the two assays instead.

284

#### 285 Comparison of MNTs

We compared the results of the NAb titers of two different laboratories with the same convalescent, preand post-vaccination serum panels as with FMIA and EIA. The correlation between NAb titers of the two laboratories was very strong at  $\rho=0.95$  (*P*<2.2x10-16) (Figure 5). Both MNTs classified 20/20 day 0 samples as negative and 20/20 6-week post-vaccination samples as positive. The MNT of laboratory #1 was more sensitive at 3 weeks by identifying 18/20 of samples as having NAbs compared to 12/20 of laboratory #2. Among convalescent-phase patient sera, NAbs were found in 19/20 of samples in laboratory #1 and 18/20 of the samples in laboratory #2.

293

### 294 **Discussion**

We evaluated the analytical and clinical performance of SARS-CoV-2 FMIA and compared FMIA to other serological assays. The clinical performance of the FMIA was excellent, reaching 100% sensitivity and specificity. The clinical performance of S-IgG FMIA did not decrease through the sample collection period (150 days or 5 months). The sensitivity of IgA- and IgM-FMIA decreased with increasing DPOs, consistent with the shorter half-lives of IgA and IgM antibodies [22].

FMIA performed well in comparison to the in-house EIA antibody test. The correlation
 between FMIA and EIA IgG and total Ig results was strong for spike glycoprotein and moderate for

nucleoprotein. Our results indicate that both methods accurately recognise vaccine-induced antibody responses at 6 weeks, but that FMIA is slightly more sensitive than EIA in samples taken 3 weeks after 1<sup>st</sup> vaccine dose. As we compared the MNTs of two laboratories, we found that NAb titers had a very strong correlation despite some differences in the methodology. Overall, the MNT of one of the laboratories was somewhat more sensitive, which is likely explained by less diluted sera and different viral strains (lineage B vs. B.1).

308 Limitations of this study are related to the sample material used in the validation process of 309 FMIA. In essence, the thresholds and DPOs described here were optimised for the detection of previous 310 infections with mild to moderate symptoms. Despite this, the S-IgG levels correlated strongly with NAb 311 titers. Our results also suggest that FMIA is better at recognising samples with NAbs than many 312 commercial assays [12]. Whilst S-IgG FMIA identified all samples with NAbs, it does not necessarily 313 measure antibodies against neutralising epitopes only, as some samples negative in MNT were considered positive for S-IgG. We conclude that FMIA is valuable in pre-screening of serum samples 314 315 prior to confirmatory MNT. As the anti-SARS-CoV-2 antibody levels have been found to correlate with 316 the disease severity [23–25], we can expect FMIA to perform well in the serological diagnostics of also 317 previous severe infections. Importantly, while the present data show an excellent sensitivity for IgG-318 FMIA until 150 DPO, its performance after that remains to be investigated.

Estimates of the persistence of immunity to COVID-19 appear to depend on the serological assay used [11,26]. We recently reported that six and twelve months after SARS-CoV-2 infection 98% and 97 % of the patients, respectively, still had S-IgG in FMIA [27]. Other recent studies have found that anti-spike IgG antibodies persist in 90% of individuals seven [28] and nine months [29] after a confirmed SARS-CoV-2 infection. We found no decrease in the sensitivity of the spike-based IgG-FMIA in samples collected up to 5 months after infection. Anti-nucleoprotein antibodies have been reported to wane faster [27,30], consistent with our findings of sensitivity decreasing from 100 to 98% for N-IgG FMIA 52-150

326 DPO. Together with data of persisting antibodies, our findings imply, that S-IgG FMIA continues to be 327 reliable in the detection of antibodies produced against SARS-CoV-2 for at least several months after 328 infection.

329 Notably, the participants providing convalescent serum samples for the positive serum 330 panel were likely all infected with a B.1 lineage virus since the samples were collected in Finland between 331 March and September 2020. However, by using two spike antigens (RBD and SFL), both of which 332 include multiple antibody binding sites, FMIA is less likely to lose performance when facing infections 333 caused by various SARS-CoV-2 variants. The combination of antigens makes FMIA also less susceptible 334 to possible cross-reactivity with antibodies produced against seasonal coronaviruses. Additionally, FMIA 335 could be used to distinguish immune response induced by COVID-19 vaccination and recent SARS-336 CoV-2 infection.

337 The need for highly sensitive and specific antibody tests will continue in the future as new 338 variants emerge fuelling further COVID-19 waves. Here we have described a reliable antibody assay for 339 the simultaneous quantification of multiple SARS-CoV-2 antibodies, with excellent clinical performance 340 and good comparability with NAb titers. We have also described the calibration of FMIA against a WHO 341 international standard, which has been reported to reduce inter-laboratory variation notably [31]. 342 However, we observed that calibrating FMIA and EIA only emphasised the differences between their 343 results. In FMIA the results are calculated from a standard curve and in EIA from the ratio between a 344 sample and two controls. Although standardisation of SARS-CoV-2 antibody assays is urgently needed, 345 our results indicate only a limited value for the international standard in calibrating two assays whose 346 test principles are quite different. The applicability and value brought by calibration should be considered 347 when used in comparisons between methodologically diverse assays.

348

349

### 350 **Conflict of interest**

NE, CV and MM are co-investigators in an unrelated study, for which THL has received research funding
from GlaxoSmithKline Vaccines. AS, AH, AK, SM, JL, PJ, LK, TD and IJ report no conflicts of interest.

### 354 Funding

The study was supported by funds from the Finnish Institute for Health and Welfare, University of Turku and the Academy of Finland (grant numbers 336439, 336431, 337527, 335527 and 335530), the Finnish Medical Foundation, the Finnish governmental subsidy for health science research and Jane and Aatos Erkko Foundation (grant number 5360-cc2fc).

359

### 360 Authors' contributions

361 CV, AH, AS, PJ and LK performed the laboratory analyses. AK, SM, LH and TD recruited the volunteers
362 and managed serum sample collection. AS and CV developed and optimised the assay. AS, NE, CV and
363 MM analysed the results. AS, JL, IJ and MM contextualised and AS, NE, AH, CV and MM drafted the
364 manuscript. All authors approved the final version.

365

# 366 Acknowledgements

367 Leena Saarinen, Marja Suorsa, Lotta Hagberg, Esa Ruokokoski, Tuomo Nieminen, Hanna Valtonen,

368 Katja Lind, Heidi Hemmilä, Tiina Pulliainen, Marja-Liisa Ollonen, Minna Haanpää, Katri Keino, Riitta

369 Santanen, Christel Pussinen, Mervi Nosa, Anne-Mari Pieniniemi and Anne Suominen.

370

# 372 **References**

- WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2021 Jul 22]. Available from: https://covid19.who.int
- Byambasuren O, Dobler CC, Bell K, et al. Comparison of seroprevalence of SARS-CoV-2
   infections with cumulative and imputed COVID-19 cases: Systematic review. PLOS ONE. 2021;
   16(4):e0248946.
- Kalish H, Klumpp-Thomas C, Hunsberger S, et al. Undiagnosed SARS-CoV-2 seropositivity
   during the first 6 months of the COVID-19 pandemic in the United States. Sci Transl Med. 2021;
   13(601).
- Hellewell J, Russell TW, Matthews R, et al. Estimating the effectiveness of routine asymptomatic
   PCR testing at different frequencies for the detection of SARS-CoV-2 infections. BMC Med.
   2021; 19(1):106.
- Huo X, Chen J, Ruan S. Estimating asymptomatic, undetected and total cases for the COVID-19
  outbreak in Wuhan: a mathematical modeling study. BMC Infect Dis. 2021; 21(1):476.
- McElfish PA, Purvis R, James LP, Willis DE, Andersen JA. Perceived Barriers to COVID-19
   Testing. Int J Environ Res Public Health. 2021; 18(5):2278.
- Nasrallah GK, Dargham SR, Shurrab F, et al. Analytic comparison between three high-throughput
   commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence
   population. Sci Rep. 2021; 11(1):11837.
- Nilsson AC, Holm DK, Justesen US, et al. Comparison of six commercially available SARS-CoV-2 antibody assays—Choice of assay depends on intended use. Int J Infect Dis. 2021; 103:381–388.
- Whitman JD, Hiatt J, Mowery CT, et al. Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nat Biotechnol. 2020; 38(10):1174–1183.
- Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol.
   2020; 5(52):eabe0367.
- Favresse J, Eucher C, Elsen M, et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on
  the Analytical Kit: A Report for Up to 10 Months after Infection. Microorganisms. 2021;
  9(3):556.
- Jääskeläinen AJ, Kuivanen S, Kekäläinen E, et al. Performance of six SARS-CoV-2
   immunoassays in comparison with microneutralisation. J Clin Virol. 2020; 129:104512.

- Trivedi SU, Miao C, Sanchez JE, et al. Development and Evaluation of a Multiplexed
  Immunoassay for Simultaneous Detection of Serum IgG Antibodies to Six Human Coronaviruses.
  Sci Rep. 2019; 9(1):1390.
- 407 14. Ekström N, Virta C, Haveri A, et al. Analytical and clinical evaluation of antibody tests for
  408 SARS-CoV-2 serosurveillance studies used in Finland in 2020. medRxiv. 2021;
  409 :2021.01.21.21250207.
- Jalkanen P, Pasternack A, Maljanen S, et al. A combination of N and S antigens with IgA and IgG
  measurement strengthens the accuracy of SARS-CoV-2 serodiagnostics. J Infect Dis. 2021;
  224(2):218–228.
- 413 16. Jalkanen P, Kolehmainen P, Häkkinen HK, et al. COVID-19 mRNA vaccine induced antibody
  414 responses against three SARS-CoV-2 variants. Nat Commun. 2021; 12(1):3991.
- 415 17. Mattiuzzo G, Bentley EM, Hassall M, et al. Establishment of the WHO International Standard and
  416 Reference Panel for anti-SARS-CoV-2 antibody. WHO/BS/20202402.

Haveri A, Smura T, Kuivanen S, et al. Serological and molecular findings during SARS-CoV-2
infection: the first case study in Finland, January to February 2020. Eurosurveillance. 2020;
25(11):2000266.

- 420 19. Dub T, Nohynek H, Hagberg L, et al. High secondary attack rate and persistence of SARS-CoV-2
  421 antibodies in household transmission study participants, Finland 2020.
- 422 20. Act on the National Institute for Health and Welfare 668/2008. [Internet]. [cited 2021 Jul 12].
  423 Available from: www.finlex.fi/en/laki/kaannokset/2008/en20080668.pdf
- 424 21. Communicable Diseases Act 1227/2016. [Internet]. [cited 2021 Jul 12]. Available from:
  425 www.finlex.fi/en/laki/kaannokset/2016/en20161227.pdf
- 426 22. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm
  427 Sci. 2004; 93(11):2645–2668.
- Chen X, Pan Z, Yue S, et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody
   responses in COVID-19. Signal Transduct Target Ther. 2020; 5(1):180.
- 430 24. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic
  431 SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200–1204.
- Röltgen K, Powell AE, Wirz OF, et al. Defining the features and duration of antibody responses to
  SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020; 5(54).
- 26. Choe PG, Kim K-H, Kang CK, et al. Antibody Responses 8 Months after Asymptomatic or Mild
  SARS-CoV-2 Infection. Emerg Infect Dis. 2021; 27(3).

436 27. Haveri A, Ekström N, Solastie A, et al. Persistence of neutralizing antibodies a year after SARS437 CoV-2 infection. medRxiv. 2021; :2021.07.13.21260426.

438 439	28.	Glück V, Grobecker S, Tydykov L, et al. SARS-CoV-2-directed antibodies persist for more the six months in a cohort with mild to moderate COVID-19. Infection. <b>2021</b> ; .		
440 441 442	29.	Yao L, Wang G-L, Shen Y, et al. Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection. J Infect Dis. <b>2021</b> ; (jiab255).		
443 444 445	30.	Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J Virol. <b>2021</b> ; 95(3):e01828-20.		
446 447	31.	Kristiansen PA, Page M, Bernasconi V, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. The Lancet. <b>2021</b> ; 397(10282):1347–1348.		

# 449 Figures and tables

	IgG	IgA	IgM
FMIA threshold (U/ml)	$\begin{aligned} \text{SFL} &\geq 0.388 \text{ \&} \\ \text{RBD} &\geq 0.712 \end{aligned}$	$SFL \ge 3.88 \&$ $RBD \ge 11.4$	$SFL \geq 17.5$
WHO standard adjusted threshold (BAU/ml)	$SFL \ge 0.089 \&$ $RBD \ge 0.13$	-	-
DPO of optimal sensitivity	13–150	13–36	13–28
Specificity [95% CI <sup>a</sup> ] (n <sup>b</sup> )	100% [99.1–100%] (n=402)	100% [99.1–100%] (n=402)	100% [99.1–100%] (n=402)
Sensitivity [95% CI <sup>a</sup> ] (n <sup>c</sup> )	100% [97.3–100%] (n=140)	100% [94.7–100%] (n=69)	100% [91.0–100%] (n=39)

450 Table 1. Thresholds, clinical specificity and clinical sensitivity of FMIA.

451

RBD = receptor binding domain of SARS-CoV-2 (Wuhan-Hu-1) spike glycoprotein. SFL = full-length
spike glycoprotein of SARS-CoV-2 (Wuhan-Hu-1). DPO = Days post-onset of symptoms. <sup>a</sup> = Wilson
confidence interval. <sup>b</sup> = Number of negative samples used for calculations. <sup>c</sup> = Number of positive
samples used for calculations, which includes only part of the positive serum panel and differs between
antibody classes due to exclusion of samples that did not meet DPO of optimal sensitivity criteria.





Figure 2: Sensitivity (%) of SARS-CoV-2 FMIA and the effect of time post-onset of symptoms (DPO).
A. Anti-S (SFL and RBD) IgG FMIA. B. Anti-N IgG FMIA. C. Anti-S (SFL and RBD) IgA FMIA. D.
Anti-S (SFL) IgM FMIA. n = number of positive serum panel's samples in each DPO group. RBD =
receptor binding domain of SARS-CoV-2 (Wuhan-Hu-1) spike glycoprotein. SFL = full-length spike
glycoprotein of SARS-CoV-2 (Wuhan-Hu-1). N = SARS-CoV-2 nucleoprotein of SARS-CoV-2
(Wuhan-Hu-1).



Figure 3. Spearman correlation (ρ) and significance (*p*) between FMIA anti-spike antibody
concentrations and neutralising antibody (NAb) titers. The dashed line marks the threshold for positive
MNT result (>4). One point may represent multiple samples (n=548). RBD = receptor binding domain
of SARS-CoV-2 (Wuhan-Hu-1) spike glycoprotein. SFL = full-length spike glycoprotein of SARS-CoV2 (Wuhan-Hu-1).



Figure 4. Spearman correlation ( $\rho$ ) and significance (p) between FMIA IgG and EIA IgG and total antispike Ig antibodies in binding antibody units (BAU/ml) calibrated against WHO international standard. Dashed lines mark thresholds for positivity per antigen. One point may represent multiple samples (n=80). S1 = SARS-CoV-2 spike glycoprotein S1 subunit, RBD = receptor binding domain of SARS-CoV-2 (Wuhan-Hu-1) spike glycoprotein. SFL = full-length spike glycoprotein of SARS-CoV-2 (Wuhan-Hu-1). N = SARS-CoV-2 nucleoprotein of SARS-CoV-2 (Wuhan-Hu-1).





490 Figure 5. Spearman correlation ( $\rho$ ) and significance (p) between neutralising antibody (NAb) titers of

491 two laboratories. Dashed lines mark thresholds for positivity ( $\geq 6$  for laboratory #1 and  $\geq 20$  for laboratory

492 #2). One point may represent multiple samples (n=80).

